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background:  Plasma surfactant proteins (SP) are markers of alveolar-capillary barrier integrity, and were shown to be elevated in acute 
decompensated HF (ADHF). We aimed to examine the kinetics of SP, and correlations with dyspnea and markers of congestion in patients with ADHF.
Methods:  We measured SP-A and SP-D in 71 patients enrolled in the DOSE biomarker sub-study, at baseline (BL), day 3, day 7/discharge, and 
day 60 using ELISA immunoassays. Multivariable regression models were used to identify correlates of BL SP levels. Temporal changes (Δ) of SP were 
examined with repeated measures model. SP Δ from BL to day 3 were correlated with weight Δ, net fluid loss and dyspnea improvement, using visual 
analog scale area under the curve (D-VAS AUC).
results:  Approximately 50% of patients had elevated SP-A levels at BL (median = 64ng/mL; 25th, 75th percentiles = 46, 83; upper limit normal 
[ULN] = 65.4ng/mL), while most had normal BL SP-D levels (median = 293ng/mL; 214, 467; ULN= 538ng/mL). Age (P=0.02 for SP-A; 0.01 for SP-
D) and COPD (P = 0.03 for SP-A; 0.04 for SP-D) were independently associated with higher BL SP levels. No significant Δ in SP levels were observed 
(Fig). There were no significant correlations between SP Δ (SP-A & SP-D) and weight Δ (P>0.10), net fluid loss (P>0.50), and D-VAS AUC (P>0.70) 
from BL to day 3.
conclusion:  The lack of dynamic changes and associations with established congestion markers or symptoms appears to limit the utility of SP-A 
and SP-D for monitoring clinical response among patients with ADHF.
 
